Viruses, human biological materials and quality solutions for research
and technological development.
The Fiocruz Covid-19 Biobank (BC19-Fiocruz) is one of the actions of the Oswaldo Cruz Foundation to fight the Covid-19 pandemic. Funded by the Ministry of Health, the initiative aims to provide an adequate infrastructure for the safe, reliable, ethical, legal and traceable storage of human and non-human biological material (viruses) related to SARS-CoV-2 and its variants. BC19-Fiocruz is a great legacy for research, technological development and innovation in health care.
The Presidency of Fiocruz inaugurates this Monday (12/13) the COVID-19 Biobank (BC19-Fiocruz), a pioneering initiative that gathers human and non-human materials in a single infrastructure. BC19-Fiocruz is one of the Foundation's actions to face the Covid-19 pandemic and constitutes a legacy for research, technological development, and innovation in health care.
BC19-Fiocruz is a biotechnology infrastructure and a provider center of biological materials and services, which enables collaborative actions at national and international levels.
The services offered by BC19-Fiocruz are related to the Collection of Human Biological Material and the Virus Collection.
Isolation, identification, authentication, preservation and delivery of isolates of the novel coronavirus SARS-CoV-2 and its variants are performed within this Collection
Under this Collection, Covid-19 related human biological material will be provided for research and technological development purposes.
| Por: Elisandra Galvão | VPPCB/Fiocruz
Discussion took place (3/23) in the session 'Building capacity to ensure benefit sharing from the global DSI system', organized by the DSI Scientific Network.
| Por: VPPCB/Fiocruz
Information about BC19-Fiocruz was released in the April newsletter of the Global Genome Biodiversity Network (GGBN).
| Por: Elisandra Galvão | VPPCB/Fiocruz
A committee formed by representatives of the Japan International Cooperation Agency (JICA) and the National Institute of Infectious Diseases (NIID), both based in Tokyo (Japan), visited Fiocruz Covid-19 Biobank (BC19-Fiocruz) this week.